| Name | GGTI-2418 |
| Description | GGTI-2418 is a highly potent, competitive, and selective inhibitor of geranylgeranyltransferase I (GGTase I), exhibiting inhibitory activities with IC50 values of 9.5 nM for GGTase I and 53 μM for FTase, respectively. Additionally, it enhances p27(Kip1) expression and induces significant regression of breast tumors. |
| In vitro | In HeLa cells, GGTI-2418 (10-15 μM; 16 hours) can delocalize FBXL2 and stabilize IP3R3[2]. |
| In vivo | GGTI-2418 (100 mg/kg daily; 5 days) induces regression of ErbB2-driven mammary tumors in ErbB2 transgenic mice. GGTI-2418 inhibits the geranylgeranylation of Rap1, significantly reduces Akt S473 phosphorylation, and upregulates p27 levels in vivo. Additionally, GGTI-2418 (100 mg/kg daily or 200 mg/kg every third day; 15 days) significantly inhibits the growth of MDA-MB-231 breast tumor xenografts in nude mice. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 100 mg/mL (226.49 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 4 mg/mL (9.06 mM), Sonication is recommended.
|
| Keywords | GGTI-2418 | GGTI 2418 | GGTase I | FTase |
| Inhibitors Related | Stavudine | Aceglutamide | Urea | Tamoxifen | Cysteamine hydrochloride | D(+)-Raffinose pentahydrate | Metronidazole | Citric Acid Triammonium | Formamide | Dimethyl phthalate | Alginic acid | Sildenafil citrate |
| Related Compound Libraries | Bioactive Compound Library | ReFRAME Related Library | Anti-Breast Cancer Compound Library | Drug Repurposing Compound Library | Post-Translational Modification Compound Library | Metabolism Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library |